Voltas, HCL Tech & more: Stocks to look out for today; check details

Nuvama has a reduce rating on Voltas with the target price at Rs 1,170. Analysts said that the company indicated that near-term demand remains weak due to elevated channel inventory (~45 days) and seasonally soft Nov–Dec demand.

The company expects a sequential improvement in Q3FY26, partly aided by pre-buying by channel ahead of anticipated price increases given the cost inflation and change in rating table. Analysts cut Voltas’s FY26/FY27 earnings per share (EPS) by 12%/3% to reflect lower margin expectations.Kotak Institutional Equities has an add rating on SBI Cards with the target price at Rs 975. Analysts said that the company’s management said that its asset quality is likely to improve, led by a decline in the formation of special mention account and its flow rates; there is a recovery in spends and it would be able to defend its market share; loan growth would be gradual; and the cost-income ratio is likely at 55-57%.CLSA has an outperform rating on Dalmia Bharat with the target price at Rs 2,650. Analysts said that the company’s management highlighted an expected high-single-digit volume growth for Q3FY26, supported by sequential improvements in Nov and Dec following a prolonged monsoon. However, pricing remains weak, especially in the eastern region, declining by about 3-4% on a blended basis, which will likely impact margins for the quarter.

The company reiterated its disciplined pricing approach, avoiding aggressive discounting to chase market share. On organic growth front, Jaisalmer greenfield expansion remains a key optionality, with limestone reserves acquired at a 20% premium, and land acquisition & clearances in an advanced stage.Morgan Stanley has an equal weight on HCL Technologies with the target price at Rs 1,680. Analysts said the company has announced another acquisition of assets carved out by HPE in telecoms services.

However, analysts believe that the financial impact of the acquisition may not be significant for the company. Total cash consideration for the acquisition is $160 million (including incentives). The company has not disclosed financial details (revenues, margins) of the acquired assets.Citigroup maintained its buy rating on Divis Laboratories with the target price at Rs 9,140. Analysts said that the US Biosecure Act is likely to become a law after the Senate passed the NDAA and has now been sent to the White House for Presidential approval.

Latest version does not name specific companies, unlike earlier drafts. However, the US Deputy Secretary of Defense earlier had flagged some China-based firms for possible inclusion under Section 1260H.

The ongoing global supply-chain diversification by innovator pharma companies could benefit Indian CDMOs.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)